Mylan Publishes Supplement to Meda Offer Document

HERTFORDSHIRE, England, and PITTSBURGH, July 21, 2016 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Hong Kong, Japan, Canada, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law (including the Takeover Rules), Dutch law, United Kingdom law, Danish law, Irish law and U.S. law.

Logo - http://photos.prnewswire.com/prnh/20140423/77793

Mylan N.V. (NASDAQ, TASE: MYL) today announced the publication of supplements to the offer documents published in connection with Mylan's recommended public offer to the shareholders of Meda Aktiebolag (publ.) to tender all their shares in Meda to Mylan (the "Offer"). The Offer was initially announced on Feb. 10, 2016.

The supplements to the offer document (the "Offer Document") and the prospectus issued in connection with the Offer (the "EU Prospectus") (the "Supplements") include Meda's interim report for Jan.-June 2016 released on July 21, 2016. The Supplements have been approved by the Swedish Financial Supervisory Authority (Sw: Finans-inspektionen) (the "SFSA") and the Netherlands Authority for the Financial Markets (Autoriteit Financiële Markten) (the "AFM") on July 21, 2016 and are made public today by Mylan.

The Offer Document and the EU Prospectus were each made public on June 16, 2016. Mylan has also filed a Registration Statement on Form S-4 (the "Registration Statement") which was declared effective on June 16, 2016.

Further information about the Offer

The Offer documents referred to above, the Supplements and further information about the Offer are available at: medatransaction.mylan.com.

Mylan discloses the information provided herein pursuant to the Swedish Financial Instruments Trading Act and the Nasdaq Stockholm's Takeover Rules (the "Takeover Rules"). The information was submitted for publication on July 21, 2016, 19:00 CET.

Additional Information

In connection with the Offer, the Offer Document was approved by the SFSA and published by Mylan on June 16, 2016. In addition, Mylan has filed certain materials with the U.S. Securities and Exchange Commission (the "SEC"), including, among other materials, the Registration Statement, which was declared effective on June 16, 2016. The EU Prospectus was approved by the AFM and published by Mylan on June 16, 2016. This communication is not intended to be, and is not, a substitute for such documents or for any other document that Mylan may file with the SFSA, the SEC, the AFM or any other competent EU authority in connection with the Offer. This communication contains advertising materials (reclame-uitingen) in connection with the Offer as referred to in Section 5:20 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). INVESTORS AND SECURITYHOLDERS OF MEDA IN SWEDEN AND INVESTORS AND SECURITYHOLDERS OF MEDA IN THE EUROPEAN ECONOMIC AREA BUT OUTSIDE OF SWEDEN ARE URGED TO READ THE OFFER DOCUMENT APPROVED BY THE SFSA AND ANY SUPPLEMENT THERETO, OR THE EU PROSPECTUS APPROVED BY THE AFM AND ANY SUPPLEMENT THERETO, AS APPLICABLE, CAREFULLY AND IN THEIR ENTIRETY BEFORE MAKING AN INVESTMENT DECISION BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MYLAN, MEDA AND THE OFFER. INVESTORS AND SECURITYHOLDERS OF MEDA OUTSIDE THE EUROPEAN ECONOMIC AREA ARE URGED TO READ ANY DOCUMENTS FILED WITH THE SFSA, THE SEC AND THE AFM OR ANY OTHER COMPETENT EU AUTHORITY CAREFULLY AND IN THEIR ENTIRETY BEFORE MAKING AN INVESTMENT DECISION BECAUSE THEY WILL EACH CONTAIN IMPORTANT INFORMATION ABOUT MYLAN, MEDA AND THE OFFER. Such documents are or upon publication will be available free of charge through the website maintained by the SEC at www.sec.gov, on Mylan's website at medatransaction.mylan.com or, to the extent filed with the AFM, through the website maintained by the AFM at www.afm.nl, or by directing a request to Mylan at [phone] or [e-mail]. Any materials filed by Mylan with the SFSA, the SEC, the AFM or any other competent EU authority that are required to be mailed to Meda shareholders will also be mailed to such shareholders. A copy of this communication will be available free of charge at the following website: medatransaction.mylan.com.